These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
163 related articles for article (PubMed ID: 38035110)
1. Optimal combination of MYCN differential gene and cellular senescence gene predicts adverse outcomes in patients with neuroblastoma. Tan J; Wang C; Jin Y; Xia Y; Gong B; Zhao Q Front Immunol; 2023; 14():1309138. PubMed ID: 38035110 [TBL] [Abstract][Full Text] [Related]
2. Transcript signatures that predict outcome and identify targetable pathways in MYCN-amplified neuroblastoma. Hallett RM; Seong AB; Kaplan DR; Irwin MS Mol Oncol; 2016 Nov; 10(9):1461-1472. PubMed ID: 27599694 [TBL] [Abstract][Full Text] [Related]
3. Metronomic topotecan impedes tumor growth of MYCN-amplified neuroblastoma cells in vitro and in vivo by therapy induced senescence. Taschner-Mandl S; Schwarz M; Blaha J; Kauer M; Kromp F; Frank N; Rifatbegovic F; Weiss T; Ladenstein R; Hohenegger M; Ambros IM; Ambros PF Oncotarget; 2016 Jan; 7(3):3571-86. PubMed ID: 26657295 [TBL] [Abstract][Full Text] [Related]
4. Druggable epigenetic suppression of interferon-induced chemokine expression linked to Seier JA; Reinhardt J; Saraf K; Ng SS; Layer JP; Corvino D; Althoff K; Giordano FA; Schramm A; Fischer M; Hölzel M J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34016720 [TBL] [Abstract][Full Text] [Related]
5. Integration of clinical characteristics and molecular signatures of the tumor microenvironment to predict the prognosis of neuroblastoma. Cheng H; Zhang L; Yang S; Ren Q; Chang S; Jin Y; Mou W; Qin H; Yang W; Zhang X; Zhang W; Wang H J Mol Med (Berl); 2023 Nov; 101(11):1421-1436. PubMed ID: 37712965 [TBL] [Abstract][Full Text] [Related]
6. MYCN Amplification Is Associated with Reduced Expression of Genes Encoding γ-Secretase Complex and NOTCH Signaling Components in Neuroblastoma. Agarwal P; Glowacka A; Mahmoud L; Bazzar W; Larsson LG; Alzrigat M Int J Mol Sci; 2023 May; 24(9):. PubMed ID: 37175848 [TBL] [Abstract][Full Text] [Related]
7. [A comprehensive analysis of potential prognostic biomarkers for MYCN-amplified neuroblastoma]. Fan X; Lu HT; Hou L; Zhang L; Yang BY; Chen WM; Zhang HY; Chen X; Li FJ Zhongguo Dang Dai Er Ke Za Zhi; 2020 Mar; 22(3):262-268. PubMed ID: 32204764 [TBL] [Abstract][Full Text] [Related]
8. Identification of hub genes and their correlation with infiltration of immune cells in Chen J; Sun M; Chen C; Jiang B; Fang Y Front Immunol; 2022; 13():1016683. PubMed ID: 36311753 [TBL] [Abstract][Full Text] [Related]
9. PD-L1-expressing natural killer cells predict favorable prognosis and response to PD-1/PD-L1 blockade in neuroblastoma. Song M; Huang Y; Hong Y; Liu J; Zhu J; Lu S; Wang J; Sun F; Huang J; Xu J; Tang Y; Xia JC; Zhang Y Oncoimmunology; 2024; 13(1):2289738. PubMed ID: 38125723 [TBL] [Abstract][Full Text] [Related]
10. SESN1 functions as a new tumor suppressor gene via Toll-like receptor signaling pathway in neuroblastoma. Hua Z; Chen B; Gong B; Lin M; Ma Y; Li Z CNS Neurosci Ther; 2024 Mar; 30(3):e14664. PubMed ID: 38516781 [TBL] [Abstract][Full Text] [Related]
11. BLM germline and somatic PKMYT1 and AHCY mutations: Genetic variations beyond MYCN and prognosis in neuroblastoma. Novak EM; Halley NS; Gimenez TM; Rangel-Santos A; Azambuja AM; Brumatti M; Pereira PL; Vince CS; Giorgi RR; Bendit I; Cristofani LM; Odone-Filho V Med Hypotheses; 2016 Dec; 97():22-25. PubMed ID: 27876123 [TBL] [Abstract][Full Text] [Related]
12. Genomic profile of MYCN non-amplified neuroblastoma and potential for immunotherapeutic strategies in neuroblastoma. Lee E; Lee JW; Lee B; Park K; Shim J; Yoo KH; Koo HH; Sung KW; Park WY BMC Med Genomics; 2020 Nov; 13(1):171. PubMed ID: 33172452 [TBL] [Abstract][Full Text] [Related]
13. The deubiquitinase USP28 maintains the expression of the transcription factor MYCN and is essential in neuroblastoma cells. Li J; Peng J; Wu L; Shen X; Zhen X; Zhang Y; Ma H; Xu Y; Xiong Q; Zhu Q; Zhang P J Biol Chem; 2023 Jul; 299(7):104856. PubMed ID: 37230388 [TBL] [Abstract][Full Text] [Related]
14. LncRNA AC142119.1 facilitates the progression of neuroblastoma by epigenetically initiating the transcription of MYCN. Yang R; Liu N; Li T; Liu F; Zhang J; Zhao H; Zou L; He X J Transl Med; 2023 Sep; 21(1):659. PubMed ID: 37741985 [TBL] [Abstract][Full Text] [Related]
15. Dzieran J; Rodriguez Garcia A; Westermark UK; Henley AB; Eyre Sánchez E; Träger C; Johansson HJ; Lehtiö J; Arsenian-Henriksson M Proc Natl Acad Sci U S A; 2018 Feb; 115(6):E1229-E1238. PubMed ID: 29374092 [TBL] [Abstract][Full Text] [Related]
16. Co-expression analysis identifies long noncoding RNA SNHG1 as a novel predictor for event-free survival in neuroblastoma. Sahu D; Hsu CL; Lin CC; Yang TW; Hsu WM; Ho SY; Juan HF; Huang HC Oncotarget; 2016 Sep; 7(36):58022-58037. PubMed ID: 27517149 [TBL] [Abstract][Full Text] [Related]
17. Age related gene DST represents an independent prognostic factor for MYCN non-amplified neuroblastoma. Wang H; Wang X; Xu L; Zhang J; Cao H BMC Pediatr; 2021 Jun; 21(1):272. PubMed ID: 34116676 [TBL] [Abstract][Full Text] [Related]
19. Human embryonic stem cell-derived neural crest model unveils CD55 as a cancer stem cell regulator for therapeutic targeting in MYCN-amplified neuroblastoma. Weng Z; Lin J; He J; Gao L; Lin S; Tsang LL; Zhang H; He X; Wang G; Yang X; Zhou H; Zhao H; Li G; Zou L; Jiang X Neuro Oncol; 2022 Jun; 24(6):872-885. PubMed ID: 34655293 [TBL] [Abstract][Full Text] [Related]
20. Proliferation and Survival of Embryonic Sympathetic Neuroblasts by MYCN and Activated ALK Signaling. Kramer M; Ribeiro D; Arsenian-Henriksson M; Deller T; Rohrer H J Neurosci; 2016 Oct; 36(40):10425-10439. PubMed ID: 27707976 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]